Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER1 | P34995 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | PTGDR2 | Q9Y5Y4 | 3/20 | 0.46 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.46 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4656398 | 0.86 | PTGER1 (0.52) | PTGER1PTGDR2PTGDR | |
| SCHEMBL27533944 | 0.84 | SMN1; SMN2 (0.60) | GAASMN1; SMN2PTGDR2PTGDRMAPT | |
| SCHEMBL8403470 | 0.82 | MAPT (0.54) | KMT2AGAASMN1; SMN2PTGDR2PTGDR | |
| SCHEMBL13342992 | 0.82 | MAPT (0.59) | KMT2ASMN1; SMN2L3MBTL1MEN1MAPT | |
| SCHEMBL27374983 | 0.81 | TDP1 (0.61) | GAAL3MBTL1MAPTLMNAALDH1A1 | |
| SCHEMBL14058725 | 0.80 | TSHR (0.58) | GAAPTGDR2PTGDRL3MBTL1MAPT | |
| SCHEMBL4626196 | 0.78 | MAPT (0.55) | PTGER1KMT2AL3MBTL1MEN1MAPT | |
| SCHEMBL8402620 | 0.78 | PTGDR2 (0.48) | GAASMN1; SMN2PTGDR2PTGDRMAPT | |
| SCHEMBL14419325 | 0.77 | HPGD (0.58) | GAASMN1; SMN2PTGDR2L3MBTL1MAPT | |
| SCHEMBL25337618 | 0.77 | PTGDR (0.56) | KMT2APTGDR2PTGDRL3MBTL1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080312322-A1 | Organic Compounds | NOVARTIS AG (CH) | 2008-12-18 | — | — | US | disclosed |
| EP-1888505-A1 | ORGANIC COMPOUNDS | Novartis AG (CH) | 2008-02-20 | — | — | EP | disclosed |
| WO-2006125593-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2006-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312322-A1 | Organic Compounds | NR3C2, MRGPRX2, HRH2 | PTGER1 81/4885KMT2A 1769/4885GAA 3324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.